• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用自动定量分析对卵巢癌组织芯片上的p53蛋白表达水平进行分析,可阐明具有预后意义的患者亚组。

Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets.

作者信息

Psyrri A, Kountourakis P, Yu Z, Papadimitriou C, Markakis S, Camp R L, Economopoulos T, Dimopoulos M A

机构信息

Department of Medical Oncology, Yale Cancer Center, New Haven, CT 06520, USA. diamando.psyrri@ yale.edu

出版信息

Ann Oncol. 2007 Apr;18(4):709-15. doi: 10.1093/annonc/mdl479. Epub 2007 Jan 13.

DOI:10.1093/annonc/mdl479
PMID:17220511
Abstract

BACKGROUND

p53 protein is regarded as a valuable prognostic marker in cancer with a potential use as a molecular target. Here, we sought to determine the prognostic value of p53 in ovarian cancer using a novel method of compartmentalized in situ protein analysis.

PATIENTS AND METHODS

A tissue array composed of 141 advanced stage ovarian cancers uniformly treated was constructed. For evaluation of p53 protein expression, we used an immunofluorescence-based method of automated in situ quantitative measurement of protein analysis (AQUA).

RESULTS

High nuclear p53 expression levels were associated with better outcome for overall survival (OS) (P = 0.0023) and disease-free survival (P = 0.0338) at 5-years. High cytoplasmic p53 expression levels were associated with better outcome for OS (P = 0.0002). In multivariable analysis, high nuclear and high cytoplasmic p53 level with International Federation of Gynecology and Obstetrics (FIGO) stage were the most significant predictor variables for OS and high nuclear p53 level with FIGO stage were the significant predictor variables for disease-free survival.

CONCLUSIONS

Assessment of the prognostic value of p53 protein levels using conventional immunohistochemistry is limited by the nonquantitative nature of the method. AQUA provides precise estimation of p53 protein levels and was able to elucidate the association of p53 protein levels and ovarian cancer prognosis.

摘要

背景

p53蛋白被视为癌症中有价值的预后标志物,具有作为分子靶点的潜在用途。在此,我们试图采用一种新的分区原位蛋白质分析方法来确定p53在卵巢癌中的预后价值。

患者与方法

构建了一个由141例接受统一治疗的晚期卵巢癌组成的组织芯片。为评估p53蛋白表达,我们采用了基于免疫荧光的蛋白质分析自动原位定量测量方法(AQUA)。

结果

5年时,高核p53表达水平与总生存期(OS)(P = 0.0023)和无病生存期(P = 0.0338)的较好预后相关。高细胞质p53表达水平与OS的较好预后相关(P = 0.0002)。在多变量分析中,高核和高细胞质p53水平与国际妇产科联盟(FIGO)分期是OS最显著的预测变量,高核p53水平与FIGO分期是无病生存期的显著预测变量。

结论

使用传统免疫组织化学评估p53蛋白水平的预后价值受到该方法非定量性质的限制。AQUA可精确估计p53蛋白水平,并能够阐明p53蛋白水平与卵巢癌预后的关联。

相似文献

1
Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets.使用自动定量分析对卵巢癌组织芯片上的p53蛋白表达水平进行分析,可阐明具有预后意义的患者亚组。
Ann Oncol. 2007 Apr;18(4):709-15. doi: 10.1093/annonc/mdl479. Epub 2007 Jan 13.
2
Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer.细胞周期蛋白依赖性激酶抑制剂p27的亚细胞定位和蛋白水平可独立预测上皮性卵巢癌的生存期。
Clin Cancer Res. 2005 Dec 1;11(23):8384-90. doi: 10.1158/1078-0432.CCR-05-1270.
3
Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer.表皮生长因子受体表达水平对上皮性卵巢癌患者生存的影响。
Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8637-43. doi: 10.1158/1078-0432.CCR-05-1436.
4
p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma.通过免疫组织化学检测p53蛋白作为上皮性卵巢癌患者的预后因素。
Cancer. 1995 Oct 1;76(7):1201-8. doi: 10.1002/1097-0142(19951001)76:7<1201::aid-cncr2820760716>3.0.co;2-l.
5
Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis.运用自动定量分析检测激肽释放酶相关肽酶8蛋白水平在晚期卵巢癌中的表达及其预后意义
Thromb Haemost. 2009 Mar;101(3):541-6.
6
Prognostic value of kallikrein-related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA).通过自动定量分析(AQUA)评估激肽释放酶相关肽酶6蛋白表达水平在晚期卵巢癌中的预后价值。
Cancer Sci. 2008 Nov;99(11):2224-9. doi: 10.1111/j.1349-7006.2008.00942.x. Epub 2008 Oct 9.
7
Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression.人组织激肽释放酶7,一种使用新型蛋白质表达原位定量方法检测晚期卵巢癌的新型生物标志物。
Ann Oncol. 2008 Jul;19(7):1271-1277. doi: 10.1093/annonc/mdn035. Epub 2008 Mar 5.
8
Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma.突变型p53蛋白过表达与高分化或中分化卵巢癌患者的不良预后相关。
Cancer. 1995 Mar 15;75(6):1327-38. doi: 10.1002/1097-0142(19950315)75:6<1327::aid-cncr2820750615>3.0.co;2-p.
9
The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma.p53肿瘤抑制基因改变在卵巢癌中的预后意义。
Cancer. 2000 Nov 1;89(9):2006-17. doi: 10.1002/1097-0142(20001101)89:9<2006::aid-cncr18>3.3.co;2-z.
10
Quantification of p53 in epithelial ovarian cancer.上皮性卵巢癌中p53的定量分析。
Gynecol Oncol. 1997 Sep;66(3):435-8. doi: 10.1006/gyno.1997.4799.

引用本文的文献

1
Direct cell interactions potentially regulate transcriptional programmes that control the responses of high grade serous ovarian cancer patients to therapy.直接的细胞相互作用可能会调节转录程序,这些转录程序控制着高级别浆液性卵巢癌患者对治疗的反应。
Sci Rep. 2025 Apr 25;15(1):14484. doi: 10.1038/s41598-025-98463-5.
2
Targeting sine oculis homeoprotein 1 (SIX1): A review of oncogenic roles and potential natural product therapeutics.靶向无眼同源蛋白1(SIX1):致癌作用及潜在天然产物疗法综述
Heliyon. 2024 Jun 17;10(12):e33204. doi: 10.1016/j.heliyon.2024.e33204. eCollection 2024 Jun 30.
3
The nuclear factor erythroid 2-related factor 2/p53 axis in breast cancer.
乳腺癌中的核因子红细胞 2 相关因子 2/p53 轴。
Biochem Med (Zagreb). 2023 Oct 15;33(3):030504. doi: 10.11613/BM.2023.030504.
4
Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets.除了P53和PTEN:鉴定高级别浆液性卵巢癌中RAS/MAPK和PI3K/AKT信号通路的分子改变以确定潜在的新型治疗靶点。
Oncol Lett. 2016 Nov;12(5):3264-3272. doi: 10.3892/ol.2016.5083. Epub 2016 Sep 2.
5
A chemotherapy response classifier based on support vector machines for high-grade serous ovarian carcinoma.一种基于支持向量机的高级别浆液性卵巢癌化疗反应分类器。
Oncotarget. 2016 Jan 19;7(3):3245-54. doi: 10.18632/oncotarget.6569.
6
A cytohistological study of p53 overexpression in ovarian neoplasms.卵巢肿瘤中p53过表达的细胞组织学研究。
South Asian J Cancer. 2012 Oct;1(2):59-62. doi: 10.4103/2278-330X.103711.
7
High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer.高频率的具有 CD44/CK19 共表达的假定卵巢癌干细胞与复发性上皮性卵巢癌患者无进展间隔时间缩短相关。
Reprod Sci. 2013 May;20(5):605-15. doi: 10.1177/1933719112461183. Epub 2012 Nov 20.
8
SERS-based nanobiosensing for ultrasensitive detection of the p53 tumor suppressor.基于 SERS 的纳米生物传感用于超灵敏检测肿瘤抑制因子 p53。
Int J Nanomedicine. 2011;6:2033-42. doi: 10.2147/IJN.S23845. Epub 2011 Sep 19.
9
Multianalyte tests for the early detection of cancer: speedbumps and barriers.用于癌症早期检测的多分析物检测:障碍与阻碍
Biomark Insights. 2007 Jul 10;2:261-7.
10
The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer.p53 作为卵巢癌化疗反应替代标志物的作用。
J Cancer Res Clin Oncol. 2010 Jan;136(1):79-88. doi: 10.1007/s00432-009-0639-8.